Precision Medicine for Patients With Identified Actionable Mutations

NCT04111107 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

45

Enrollment

OTHER

Sponsor class

Stopped PI left the institution and site decided not to continue the study

Conditions

Solid Tumor
Lymphoma
Multiple Myeloma
Malignant Neoplasm
Mutation Abnormality

Interventions

DRUG: Investigational Agent
OTHER: Supportive Care Regimens
DIAGNOSTIC_TEST: Next Gen Sequencing Report

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]